BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus-Reference-Cited by-同舟云学术

BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus

Published:2010-03-05 Issue:12 Volume:127 Page:2965-2973
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Liu Dingxie,Xing Joanna,Trink Barry,Xing Mingzhao

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference34 articles.

1. Increasing incidence of thyroid cancer in the United States, 1973-2002;Davies;JAMA,2006

2. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

3. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer;Cooper;Thyroid,2006

4. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy;Durante;J Clin Endocrinol Metab,2006

5. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications;Xing;Endocr Rev,2007

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of antiangiogenesis tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: A meta-analysis of prospective studies;Medicine;2024-08-02

2. An immune biomarker associated with EMT serves as a predictor for prognosis and drug response in bladder cancer;Aging;2024-07-08

3. Advances in targeted therapy and biomarker research in thyroid cancer;Frontiers in Endocrinology;2024-03-04

4. The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer;Journal of Translational Medicine;2023-10-18

5. Integrated pan-cancer analysis of centromere protein F and experimental verification of its role and clinical significance in cholangiocarcinoma;Functional & Integrative Genomics;2023-05-29